Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà
MedNavigator.ru - Ïîèñê è ïîäáîð ëå÷åíèÿ â Ðîññèè è çà ðóáåæîì

Âåðíóòüñÿ   Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà > Ôîðóìû âðà÷åáíûõ êîíñóëüòàöèé > Íåâðîëîãèÿ è íåéðîõèðóðãèÿ > Ôîðóì äëÿ îáùåíèÿ âðà÷åé íåâðîëîãîâ è íåéðîõèðóðãîâ

Ôîðóì äëÿ îáùåíèÿ âðà÷åé íåâðîëîãîâ è íåéðîõèðóðãîâ Ôîðóì ïðåäíàçíà÷åí äëÿ îáùåíèÿ âðà÷åé ìåæäó ñîáîé.

Îòâåò
 
Îïöèè òåìû Ïîèñê â ýòîé òåìå Îïöèè ïðîñìîòðà
  #16  
Ñòàðûé 20.03.2012, 19:31
Àâàòàð äëÿ Gilarov
Gilarov Gilarov âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 26.07.2001
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 7,196
Ïîáëàãîäàðèëè 713 ðàç(à) çà 691 ñîîáùåíèé
Gilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Êñòàòè, èíòåðåñíî, ÷òî 30% ÈÌ ñëó÷èëèñü óæå ïîñëå îòìåíû èññëåäóåìûõïðåïàðàòîâ. À â Ðîññèè áûëî, âðîäå áû, 18 èëè 20 öåíòðîâ.
Îòâåòèòü ñ öèòèðîâàíèåì
  #17  
Ñòàðûé 21.03.2012, 09:55
Àâàòàð äëÿ MKMED
MKMED MKMED âíå ôîðóìà ÂÐÀ×
Êàíäèäàò â âåòåðàíû ôîðóìà
      
 
Ðåãèñòðàöèÿ: 05.05.2006
Ãîðîä: Óôà
Ñîîáùåíèé: 1,530
Ïîáëàãîäàðèëè 467 ðàç(à) çà 458 ñîîáùåíèé
MKMED ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMKMED ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMKMED ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMKMED ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMKMED ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMKMED ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò audovichenko Ïîñìîòðåòü ñîîáùåíèå
Òðîìáîëèçèñ ïðîòèâîïîêàçàí êàê íà âàðôàðèíå, òàê è íà äàáèãàòðàíå.
Åñëè ÌÍÎ ìåíåå 1,4, òî âàðôàðèí íå ÿâëÿåòñÿ àáñîëþòíûì ïðîòèâîïîêàçàíèåì äëÿ òðîìáîëèçèñà.
Îòâåòèòü ñ öèòèðîâàíèåì
  #18  
Ñòàðûé 21.03.2012, 09:57
Àâàòàð äëÿ MKMED
MKMED MKMED âíå ôîðóìà ÂÐÀ×
Êàíäèäàò â âåòåðàíû ôîðóìà
      
 
Ðåãèñòðàöèÿ: 05.05.2006
Ãîðîä: Óôà
Ñîîáùåíèé: 1,530
Ïîáëàãîäàðèëè 467 ðàç(à) çà 458 ñîîáùåíèé
MKMED ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMKMED ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMKMED ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMKMED ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMKMED ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMKMED ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîãëàøóñü ñî âñåì, êðîìå òîãî, ÷òî àñïèðèí - àëüòåðíàòèâà äëÿ ïàöèåíòîâ ñ óìåðåííûì ðèñêîì. Àñïèðèí, óâû, ïðàêòè÷åñêè áåñïîëåçåí â êà÷åñòâå ñðåäñòâà ïðîôèëàêòèêè òðîìáîýìáîëèé ïðè ÔÏ. Óæ åñëè ãîâîðèòü îá àëüòåðíàòèâàõ èç íûíå äîñòóïíûõ, òî ýòî êîìáèíàöèÿ àñïèðèíà è êëîïè. Íó, è êñàáàíû, êîíå÷íî (õîòÿ èõ ïîêà â ÐÔ â ïðîäàæå íåò).

Ê ñîæàëåíèþ íå ïðèõîäèëîñü âñòðå÷àòüñÿ ñ ñåðüåçíûìè èññëåäîâàíèÿìè ïî ýôôåêòèâíîñòè äàííîé êîìáèíàöèè â ïðîôèëàêòèêå èíñóëüòà ïðè ÔÏ.
Îòâåòèòü ñ öèòèðîâàíèåì
  #19  
Ñòàðûé 21.03.2012, 10:39
tambofff tambofff âíå ôîðóìà ÂÐÀ×
Ïîñòîÿííûé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 25.11.2010
Ãîðîä: Òàìáîâ
Ñîîáùåíèé: 228
Ñêàçàë(à) ñïàñèáî: 19
Ïîáëàãîäàðèëè 15 ðàç(à) çà 13 ñîîáùåíèé
tambofff ýòîò ó÷àñòíèê èìååò õîðîøóþ ðåïóòàöèþ íà ôîðóìå
À êàê æå óïîìÿíóòîå Gilarov èññëåäîâàíèå ACTIVE (W, A)?
Îòâåòèòü ñ öèòèðîâàíèåì
  #20  
Ñòàðûé 21.03.2012, 17:42
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,618
Ïîáëàãîäàðèëè 33,353 ðàç(à) çà 31,698 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
 èññëåäîâàíèè ACTIVE äîáàâëåíèå êëîïèäîãðåëÿ ê àñïèðèíó ñíèæàëî ðèñê èíñóëüòà, íî ïîâûøàëî ðèñê áîëüøèõ êðîâîòå÷åíèé... â íåäàâíåé ïóáëèêàöèè íåò-áåíåôèòû îò äîáàâëåíèÿ êëîïèäîãðåëÿ ñòàò. íåäîñòîâåðíû:

Adding clopidogrel to aspirin therapy prevented 0.57 ischemic stroke equivalent (95% CI, -0.12 to 1.24) per 100 patient-years of treatment when weighted by hazard for death after ischemia or hemorrhage and 0.67 ischemic stroke equivalent (CI, -0.03 to 1.18) when weighted by death or disability after ischemia or hemorrhage.
---
Ann Intern Med. 2011 Nov 1;155(9):579-86. Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable.

è ïîõîæå äàííàÿ êîìáèíàöèÿ öåíîâî-ýôôåêòèâíà òîëüêî äëÿ îïðåäåëåííîé ãðóïïû ïàöèåíòîâ: clopidogrel plus aspirin appears cost-effective compared to aspirin alone for stroke prevention in patients with AF with a CHADS(2) of ≥2 and a lower risk of bleeding.
---
Am J Cardiol. 2012 Jan 3. Cost-Effectiveness of Clopidogrel Plus Aspirin for Stroke Prevention in Patients With Atrial Fibrillation in Whom Warfarin Is Unsuitable.
__________________
Èñêðåííå,
Âàäèì Âàëåðüåâè÷.
Îòâåòèòü ñ öèòèðîâàíèåì
  #21  
Ñòàðûé 21.03.2012, 20:56
Àâàòàð äëÿ Gilarov
Gilarov Gilarov âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 26.07.2001
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 7,196
Ïîáëàãîäàðèëè 713 ðàç(à) çà 691 ñîîáùåíèé
Gilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò MKMED Ïîñìîòðåòü ñîîáùåíèå
Ê ñîæàëåíèþ íå ïðèõîäèëîñü âñòðå÷àòüñÿ ñ ñåðüåçíûìè èññëåäîâàíèÿìè ïî ýôôåêòèâíîñòè äàííîé êîìáèíàöèè â ïðîôèëàêòèêå èíñóëüòà ïðè ÔÏ.
Äî âíåäðåíèÿ êñàáàíîâ/ãàòðàíîâ âñåðüåç ïðåäëàãàëîñü èñïîëüçîâàòü àñïèðè+êëîïè â ñëó÷àå íåâîçìîæíîñòè íàçíà÷åíèÿ âàðôàðèíà. Ýòà êîìáèíàöèÿ ëó÷øå, ÷åì ïðîñòî àñïèðèí.
PS êàê áûñòðî â Âàøåì ëå÷åáíîì ó÷ðåæäåíèè îïðåäåëÿþò ÌÍÎ, åñëè ïàöèåíò ïîñòóïàåò â âå÷åðíåå èëè íî÷íîå âðåìÿ?
Îòâåòèòü ñ öèòèðîâàíèåì
  #22  
Ñòàðûé 22.03.2012, 08:53
tambofff tambofff âíå ôîðóìà ÂÐÀ×
Ïîñòîÿííûé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 25.11.2010
Ãîðîä: Òàìáîâ
Ñîîáùåíèé: 228
Ñêàçàë(à) ñïàñèáî: 19
Ïîáëàãîäàðèëè 15 ðàç(à) çà 13 ñîîáùåíèé
tambofff ýòîò ó÷àñòíèê èìååò õîðîøóþ ðåïóòàöèþ íà ôîðóìå
Äàæå åñëè ïîòîðîïèòü ìåäñåñò¸ð, çàáèðàþùèõ êðîâü, ñàíèòàðîê, îòíîñÿùèõ êðîâü, è ëàáîðàòîðèþ (÷åãî íè òå, íè äðóãèå, íè òðåòüè ñèëüíî íå ëþáÿò) - ìèíèìóì 20 ìèíóò.
Îòâåòèòü ñ öèòèðîâàíèåì
  #23  
Ñòàðûé 23.03.2012, 10:52
Àâàòàð äëÿ Gilarov
Gilarov Gilarov âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 26.07.2001
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 7,196
Ïîáëàãîäàðèëè 713 ðàç(à) çà 691 ñîîáùåíèé
Gilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Âàì êðóïíî ïîâåçëî.  íàøåé áîëüíèöå âå÷åðîì, íî÷üþ è ïî âûõîäíûì ÌÍÎ íå îïðåäåëÿþò âîâñå.
Îòâåòèòü ñ öèòèðîâàíèåì
  #24  
Ñòàðûé 23.03.2012, 15:35
tambofff tambofff âíå ôîðóìà ÂÐÀ×
Ïîñòîÿííûé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 25.11.2010
Ãîðîä: Òàìáîâ
Ñîîáùåíèé: 228
Ñêàçàë(à) ñïàñèáî: 19
Ïîáëàãîäàðèëè 15 ðàç(à) çà 13 ñîîáùåíèé
tambofff ýòîò ó÷àñòíèê èìååò õîðîøóþ ðåïóòàöèþ íà ôîðóìå
Ðå÷ü øëà î ðåãèîíàëüíîì ñîñóäèñòîì öåíòðå - òàê ÷òî, âîçìîæíî, ýòî äàæå äîëãî. Ïðî òðîìáîëèçèñ íà ôîíå âàðôàðèíà ïðè ÌÍÎ ìåíåå 1,4 - âàæíîå äîïîëíåíèå (óòî÷íèì - âðîäå íå áîëåå 1,3).
Îòâåòèòü ñ öèòèðîâàíèåì
  #25  
Ñòàðûé 23.03.2012, 16:57
Àâàòàð äëÿ MKMED
MKMED MKMED âíå ôîðóìà ÂÐÀ×
Êàíäèäàò â âåòåðàíû ôîðóìà
      
 
Ðåãèñòðàöèÿ: 05.05.2006
Ãîðîä: Óôà
Ñîîáùåíèé: 1,530
Ïîáëàãîäàðèëè 467 ðàç(à) çà 458 ñîîáùåíèé
MKMED ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMKMED ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMKMED ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMKMED ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMKMED ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMKMED ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò Gilarov Ïîñìîòðåòü ñîîáùåíèå
Äî âíåäðåíèÿ êñàáàíîâ/ãàòðàíîâ âñåðüåç ïðåäëàãàëîñü èñïîëüçîâàòü àñïèðè+êëîïè â ñëó÷àå íåâîçìîæíîñòè íàçíà÷åíèÿ âàðôàðèíà. Ýòà êîìáèíàöèÿ ëó÷øå, ÷åì ïðîñòî àñïèðèí.
Cîâåðøåííî âåðíî, íî íàäî îãîâîðèòüñÿ: "Äî âíåäðåíèÿ êñàáàíîâ/ãàòðàíîâ êàðäèîëîãàìè âñåðüåç ïðåäëàãàëîñü èñïîëüçîâàòü àñïèðè+êëîïè â ñëó÷àå íåâîçìîæíîñòè íàçíà÷åíèÿ âàðôàðèíà "

Òàê êàê â ðåêîìåíäàöèÿõ AHA ãîâîðèòñÿ:
Öèòàòà:
An additional arm of this study (ACTIVE A) compared
aspirin versus clopidogrel plus aspirin in AF patients who
were considered “unsuitable for vitamin K antagonist therapy”
and reported a reduction in the rate of stroke with
clopidogrel plus aspirin. Stroke occurred in 296 patients
receiving clopidogrel plus aspirin (2.4% per year) and 408
patients receiving aspirin monotherapy (3.3% per year; RR,
0.72; 95% CI, 0.62 to 0.83; P0.001). Major bleeding
occurred in 251 patients receiving clopidogrel plus aspirin
(2.0% per year) and in 162 patients receiving aspirin alone
(1.3% per year; RR, 1.57; 95% CI, 1.29 to 1.92; P0.001).232
An analysis of major vascular events combined with major
hemorrhage showed no difference between the 2 treatment
options (RR, 0.97; 95% CI, 0.89 to 1.06; P0.54). The
majority of patients enrolled in this study were deemed to be
unsuitable for warfarin based on physician judgment or
patient preference; only 23% had increased bleeding risk or
inability to comply with monitoring as the reason for enrollment.
Therefore, on the basis of uncertainty of how to
identify patients who are “unsuitable” for anticoagulation, as
well as the lack of benefit in the analysis of vascular events
plus major hemorrhage, aspirin remains the treatment of
choice for AF patients who have a clear contraindication to
vitamin K antagonist therapy but are able to tolerate antiplatelet
therapy.
 íàèáîëåå ñâåæåì Êîõðàíîâñêîì îáçîðå:

Öèòàòà:
The available evidence demonstrates that the use of clopidogrel plus aspirin is associated with a reduction in the risk of cardiovascular
events and an increased risk of bleeding compared with aspirin alone. Only in patients with acute non-ST coronary syndrome benefits
outweigh harms.
ESO óïîìÿíàòü íå áóäåì, òàê êàê èì äàâíî ïîðà îáíîâëÿòü ñâîè ðåêîìåíäàöèè

Òàêèì îáðàçîì, íåâðîëîãè, áóäó÷è ëþäüìè îñòîðîæíûìè, ê ýòîé êîìáèíàöèè ïðèáåãàþò êðàéíå ðåäêî è îáû÷íî íå ïðè ÔÏ.

À ïðî ÌÍÎ - òàê âåäü èíñóëüòû íå òîëüêî íî÷üþ ñëó÷àþòñÿ.
Îòâåòèòü ñ öèòèðîâàíèåì
  #26  
Ñòàðûé 23.03.2012, 17:07
Àâàòàð äëÿ MKMED
MKMED MKMED âíå ôîðóìà ÂÐÀ×
Êàíäèäàò â âåòåðàíû ôîðóìà
      
 
Ðåãèñòðàöèÿ: 05.05.2006
Ãîðîä: Óôà
Ñîîáùåíèé: 1,530
Ïîáëàãîäàðèëè 467 ðàç(à) çà 458 ñîîáùåíèé
MKMED ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMKMED ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMKMED ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMKMED ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMKMED ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMKMED ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò tambofff Ïîñìîòðåòü ñîîáùåíèå
Ðå÷ü øëà î ðåãèîíàëüíîì ñîñóäèñòîì öåíòðå - òàê ÷òî, âîçìîæíî, ýòî äàæå äîëãî. Ïðî òðîìáîëèçèñ íà ôîíå âàðôàðèíà ïðè ÌÍÎ ìåíåå 1,4 - âàæíîå äîïîëíåíèå (óòî÷íèì - âðîäå íå áîëåå 1,3).
Òîãäà, ñïðàâåäëèâîñòè ðàäè, íàäî îòìåòèòü, ÷òî öèôðà îò AHA - 1,7
Îòâåòèòü ñ öèòèðîâàíèåì
  #27  
Ñòàðûé 24.03.2012, 11:45
tambofff tambofff âíå ôîðóìà ÂÐÀ×
Ïîñòîÿííûé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 25.11.2010
Ãîðîä: Òàìáîâ
Ñîîáùåíèé: 228
Ñêàçàë(à) ñïàñèáî: 19
Ïîáëàãîäàðèëè 15 ðàç(à) çà 13 ñîîáùåíèé
tambofff ýòîò ó÷àñòíèê èìååò õîðîøóþ ðåïóòàöèþ íà ôîðóìå
Ñëîæíî ñêàçàòü, ÷òî âàæíåå - èíñòðóêöèÿ ê ïðåïàðàòó (ãäå ÌÍÎ 1,3, à òåðàïåâòè÷åñêîå îêíî äëÿ ÎÍÌÊ - 3 ÷àñà) èëè ðåêîìåíäàöèè íåâðîëîãè÷åñêèõ ñîîáùåñòâ (ãäå ÌÍÎ 1.7, à òàêæå ýêñïåðèìåíòû â îêíå 3-4,5 ÷àñà). Ïî ìíå - ïåðâîå.
Îòâåòèòü ñ öèòèðîâàíèåì
  #28  
Ñòàðûé 25.03.2012, 20:45
Àâàòàð äëÿ Gilarov
Gilarov Gilarov âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 26.07.2001
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 7,196
Ïîáëàãîäàðèëè 713 ðàç(à) çà 691 ñîîáùåíèé
Gilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
À êàêèìè ðåêîìåíäàöèÿìè ðóêîâîäñòâóþòñÿ îñòîðîæíûå íåâðîëîãè â âûáîðå ñðåäñòâà ïðåäóïðåæäåíèÿ èíñóëüòà ïðè ÔÏ? Ðåêîìåíäàöèè ïî ÔÏ è òðîìáîïðîôèëàêòèêó ïðè íåé íàïèñàíû â ìàññå ñâîåé êàðäèîëîãàìè. Åñòü ëè ÷òî-òî íà ýòó òåìó, íàïèñàííîå íåâðîëîãàìè?
P S òàê âñå æå ÌÍÎ â Âàøåé áîëüíèöå íî÷üþ îïðåäåëÿþò?
Îòâåòèòü ñ öèòèðîâàíèåì
  #29  
Ñòàðûé 25.03.2012, 21:04
tambofff tambofff âíå ôîðóìà ÂÐÀ×
Ïîñòîÿííûé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 25.11.2010
Ãîðîä: Òàìáîâ
Ñîîáùåíèé: 228
Ñêàçàë(à) ñïàñèáî: 19
Ïîáëàãîäàðèëè 15 ðàç(à) çà 13 ñîîáùåíèé
tambofff ýòîò ó÷àñòíèê èìååò õîðîøóþ ðåïóòàöèþ íà ôîðóìå
ÌÍÎ: ÿ ñîâìåùàþ â ÐÑÖ è ãîðîäñêîé áîëüíèöå - â ïåðâîé îïðåäåëÿþò îäíîçíà÷íî, à ïðî âòîðóþ - åñëè äåæóðèò âðà÷-ëàáîðàíò (ïðàêòè÷åñêè âñå áóäíè è íå âñå âûõîäíûå) è î÷åíü ïîïðîñèòü, òî âûïîëíÿò è íî÷üþ.

Èíòåðåñíî: [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Öèòàòà:
Åñòü ëè ÷òî-òî íà ýòó òåìó, íàïèñàííîå íåâðîëîãàìè?
- ñðàçó íå îòâåòèøü.
Îòâåòèòü ñ öèòèðîâàíèåì
  #30  
Ñòàðûé 26.03.2012, 16:58
Àâàòàð äëÿ MKMED
MKMED MKMED âíå ôîðóìà ÂÐÀ×
Êàíäèäàò â âåòåðàíû ôîðóìà
      
 
Ðåãèñòðàöèÿ: 05.05.2006
Ãîðîä: Óôà
Ñîîáùåíèé: 1,530
Ïîáëàãîäàðèëè 467 ðàç(à) çà 458 ñîîáùåíèé
MKMED ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMKMED ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMKMED ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMKMED ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMKMED ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMKMED ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò Gilarov Ïîñìîòðåòü ñîîáùåíèå
À êàêèìè ðåêîìåíäàöèÿìè ðóêîâîäñòâóþòñÿ îñòîðîæíûå íåâðîëîãè â âûáîðå ñðåäñòâà ïðåäóïðåæäåíèÿ èíñóëüòà ïðè ÔÏ? Ðåêîìåíäàöèè ïî ÔÏ è òðîìáîïðîôèëàêòèêó ïðè íåé íàïèñàíû â ìàññå ñâîåé êàðäèîëîãàìè. Åñòü ëè ÷òî-òî íà ýòó òåìó, íàïèñàííîå íåâðîëîãàìè?
P S òàê âñå æå ÌÍÎ â Âàøåé áîëüíèöå íî÷üþ îïðåäåëÿþò?
Âîò ýòèìè:
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
è ïðî÷.
È òàì ýòà ñàìàÿ êîìáèíàöèÿ íèãäå íå ðåêîìåíäóåòñÿ, â îòëè÷èè îò ãàéäîâ, îïóáëèêîâàííûõ â Chest ÷èñòî êàðäèîëîãè÷åñêîé ãðóïïîé.

PS  Ñåé÷àñ ÿ ðàáîòàþ â áîëüíèöå, êîòîðàÿ íå ÿâëÿåòñÿ ñêîðîïîìîùíîé è íå ÿâëÿåòñÿ ñîñóäèñòûì öåíòðîì, ïîýòîìó ìíå íè ðàçó íå ïîíàäîáèëîñü ÌÍÎ íî÷üþ. Íî äóìàþ ýòî âîçìîæíî - ïîñòîÿííî äåæóðèò âðà÷-ëàáîðàíò.

PPS Ïîâòîðþñü - ÒËÒ ïðîâîäèòñÿ è äíåì.
Îòâåòèòü ñ öèòèðîâàíèåì
Îòâåò



Âàøè ïðàâà â ðàçäåëå
Âû íå ìîæåòå ñîçäàâàòü òåìû
Âû íå ìîæåòå îòâå÷àòü íà ñîîáùåíèÿ
Âû íå ìîæåòå ïðèêðåïëÿòü ôàéëû
Âû íå ìîæåòå ðåäàêòèðîâàòü ñîîáùåíèÿ

BB êîäû Âêë.
Ñìàéëû Âêë.
[IMG] êîä Âêë.
HTML êîä Âûêë.



×àñîâîé ïîÿñ GMT +3, âðåìÿ: 06:52.




Ðàáîòàåò íà vBulletin® âåðñèÿ 3.
Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.